We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The attorney general of Arkansas has sued generic firms Dey and Warrick Pharmaceuticals, as well as Warrick’s affiliates Schering-Plough and Schering, for misreporting their average wholesale prices (AWPs), allegedly fraudulently inflating Medicaid and Medicare reimbursement rates to physicians and other providers.
A federal appeals court has upheld the FDA’s decision to award Alpharma subsidiary Purepac the 180-day marketing exclusivity for a generic version of Pfizer’s Neurontin, which the FDA has approved for treating epilepsy.
An Atlanta jury’s decision not to hold Wyeth accountable for heart-valve injuries a woman blamed on use of the diet drug Pondimin (fenfluramine) makes future large damage awards unlikely in similar cases, according to a financial analyst who follows the company.
Eon Labs moved closer to launching a generic version of GlaxoSmithKline’s (GSK’s) profitable antidepressant Wellbutrin SR after a district court denied rival firm Andrx’s motions to block the product, and an appeals court temporarily suspended an injunction sought by GSK.
In a pair of recent generic-brand court rulings, a federal judge has issued a preliminary injunction against Eon Labs’ Wellbutrin SR generic product and another has upheld Pfizer’s patent on its antidepressant Zoloft.
A federal judge has cleared the way for generic firm Endo Pharmaceuticals to launch a version of Purdue Pharma’s pain treatment OxyContin, ruling that patents on the brand product were unenforceable.
Mylan said it would appeal a recent federal court ruling that rejected the firm’s claims that NaPro BioTherapeutics obtained its formulation patents for a generic paclitaxel product through fraud and inequitable conduct on the U.S. Patent and Trademark Office.